Obesity, brain natriuretic peptide levels and mortality in patients hospitalized with heart failure and preserved left ventricular systolic function

What Was Tested

Researchers studied BNP (Nesiritide) in this clinical trial publication.

An inverse relationship between brain natriuretic peptide (BNP) levels and body mass index (BMI) has been described for patients with left ventricular (LV) systolic dysfunction.

In this study, the association of BMI, BNP levels and mortality in patients hospitalized for heart failure with preserved LV systolic function (HFpLVF) was investigated.

Who Took Part

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

Patients were divided into categories of BMI: normal (BMI < 25 kg/m), overweight (BMI 25-29.9 kg/m) and obese (BMI ≥ 30 kg/m).

How the Study Was Run

Relevant clinical and echocardiographic characteristics and all-cause mortality were obtained through chart review.

What Was Measured

An inverse relationship between brain natriuretic peptide (BNP) levels and body mass index (BMI) has been described for patients with left ventricular (LV) systolic dysfunction.

In this study, the association of BMI, BNP levels and mortality in patients hospitalized for heart failure with preserved LV systolic function (HFpLVF) was investigated.

PubMed files the paper under topics including Adrenergic beta-Antagonists, Atrial Fibrillation, Body Mass Index, Heart Failure, Hospitalization, Natriuretic Peptide, Brain and Obesity.

What This Means in Plain Language

This is a clinical trial of BNP (Nesiritide).

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (The American journal of the medical sciences), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.